6-7393185-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001348194.2(RIOK1):c.-187G>A variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,316 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_001348194.2 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RIOK1 | NM_031480.3 | c.158G>A | p.Gly53Asp | missense_variant | 2/17 | ENST00000379834.7 | NP_113668.2 | |
RIOK1 | NM_001348194.2 | c.-187G>A | 5_prime_UTR_premature_start_codon_gain_variant | 2/17 | NP_001335123.1 | |||
RIOK1 | XM_011514933.4 | c.194G>A | p.Gly65Asp | missense_variant | 2/17 | XP_011513235.2 | ||
RIOK1 | NM_001348194.2 | c.-187G>A | 5_prime_UTR_variant | 2/17 | NP_001335123.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152116Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461200Hom.: 0 Cov.: 29 AF XY: 0.00000138 AC XY: 1AN XY: 726934
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152116Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74296
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 08, 2024 | The c.158G>A (p.G53D) alteration is located in exon 2 (coding exon 2) of the RIOK1 gene. This alteration results from a G to A substitution at nucleotide position 158, causing the glycine (G) at amino acid position 53 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at